BrainStorm Cell Therapeutics, one of the leading developers of adult stem cell therapies that mainly focuses on adult neurodegenerative diseases, reported that the company’s 28-week-long Phase II clinical trial for progressive multiple sclerosis (MS) came to a close.

Amathus Therapeutics, a biopharmaceutical company working on small molecule modulators across diverse genetically defined diseases, entered into a strategic collaboration with Merck to develop novel small molecule treatment candidates for neurodegenerative diseases.

Prescription drug watchdog GoodRx compiled a list of the 10 most expensive drugs on the market.

Seattle-based AltPep Corporation raised $23.15 million in a Series A financing round to take the company’s breakthrough amyloid targeting platform to development.

RNAi-focused Atalanta Therapeutics launched with $110 million in combined Series A funding and collaboration deals with Genentech and Biogen to address diseases related to the central nervous system, including Huntington’s, Alzheimer’s and Parkinson’s diseases.

BioSpace presented the NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.

Skyhawk Therapeutics and Vertex Pharmaceuticals inked a strategic research collaboration and licensing deal focused on developing novel small molecules that modulate RNA splicing.

Clene Nanomedicine is trying to set a new “gold standard” in neurodegenerative diseases through the development of a new class of drugs called bioenergetic nanotherapeutics that harnesses the properties of gold nanocrystals.

UCB S.A. is flexing the company’s M&A muscles once again with the acquisition of Handl Therapeutics BV, a rapidly growing and transformative gene therapy company based in Leuven, Belgium.

Biomarkers will be critical to developing precision medicine for Alzheimer’s disease, and phosphorylated tau (P-tau) may enable earlier and more accurate detection, according to Eli Lilly-associated researchers.